Navigation Links
RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds,Significant Promise for Treating Breast Cancer

growth, invasion, and metastasis. It has also been shown to have a role in preventing the patient's immune system from recognizing and destroying the tumor. It is thought that cancer therapies able to inhibit STAT3 may have profound anti-cancer effects, which may include re-establishing normal immune function against the tumor. The 4T1 animal studies, which are performed in mice that have a normal immune system, provide support for this idea. When researchers examined the spleens of tumor-bearing animals, they found that untreated control animals had a significant reduction in the number of immune cells in their spleens. Animals receiving RTA 402, however, had levels of immune cells that were consistent with healthy, cancer-free animals.

"This paper provides important new data on how RTA 402 works to inhibit the growth and metastasis of cancer," said Warren Huff, CEO of Reata. "The effects on STAT3 shown in this paper, combined with the drugs' proven inhibition of NF-kB, indicate that these agents modulate important and inter-related pathways in cancer cells."

About Reata

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on selecting and discovering promising early drug development opportunities and translating them into successful marketed drugs that target major unmet clinical needs in cancer, inflammation and neurodegenerative disease. The company's two lead programs are entering advanced clinical trials for deadly, late-stage cancers. In parallel with its clinical development, Reata is advancing a breakthrough drug discovery platform that addresses protein misfolding, a key factor in cancer and neurodegenerative disease, to feed its pipeline of small molecule therapeutic candidates. Reata takes a new and different approach to biotechnology, managing its pipeline as a portfolio of opportunities that can be advanced on a single management and physical infrastructure, streamlining the route to human trials and approval. Founded
'"/>




Page: 1 2 3

Related medicine technology :

1. RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments
2. Gabapentin Shown Effective for Fibromyalgia Pain
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
5. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
6. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
7. Accelreon Pharmas ACE-031Shown to Increase Muscle Mass in Preclinical Studies
8. Cethromycin Shown Effective Against Anthrax in Study
9. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
Post Your Comments:
(Date:6/30/2015)... 24, 2015 Research ... of the "Global Array Instruments Market 2015-2019" ... global array instruments market to grow at a ... The global array instruments market can be ... and others including tissue microarrays and cell microarrays. ...
(Date:6/30/2015)... 2015  Inari Medical, Inc. announced today that it ... financing. The financing was led by members of the ... US Venture Partners.  The round also included participation by ... very pleased to complete this financing with the support ... , who joined in February 2015 as President and ...
(Date:6/30/2015)... ALISO VIEJO, Calif. , June 30, 2015 ... from the PRISM II study showing that treatment ... statistically significant reduction in symptoms of pseudobulbar affect ... or stroke. PBA is a distressing condition characterized ... crying resulting from certain neurologic diseases or brain ...
Breaking Medicine Technology:Global Array Instruments Market 2015-2019 - Advances in Personalized Medicines with Affymetrix, Agilent Technologies & Illumina Dominating 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7
... MonoSol Rx, the developers of PharmFilm® technology and ... film products, today announced that it held a ... Food and Drug Administration (FDA) regarding the development ... a 505(b)(2) pathway.  The registration dossier of Montelukast ...
... 2011 PTC Therapeutics, Inc. (PTC) today announced the ... Medical Officer.  Dr. Spiegel served previously as Chief Medical ... of Jay Barth, M.D. to Vice President of Clinical ... Spiegel will report to Stuart W. Peltz, Ph.D., President ...
Cached Medicine Technology:MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 2MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 3PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 2PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 3
(Date:6/30/2015)... , ... June 30, 2015 , ... ... customers. As a subcontractor, ESSC ranked as one of their top 20 installing ... the last quarter of 2014. Providers are based on timeliness, service, installation, paperwork ...
(Date:6/30/2015)... ... , ... Ticket Down is a reliable source for cheap tickets for Journey at the ... band has been packing venues for years and they are one of the most beloved ... in their career. While Journey is known for their all-around great sound, fans of ...
(Date:6/30/2015)... ... June 30, 2015 , ... The board certified otolaryngologists ... design’ website to inform potential sinus surgery patients about ear, nose, and throat ... information about a wide variety of ENT issues including hearing loss, ear infections, ...
(Date:6/30/2015)... ... June 30, 2015 , ... Earlier this month Wound ... Medicine Course. Clinicians from WCA partnering hospitals across the country, met in Anaheim, ... care and hyperbaric medicine education and training is something that is never complete. ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... YouTube video, “Fireside Convalescent Care Center.” The video informs community members of Fireside’s ... continually seeing the need for those seeking care to be well informed and ...
Breaking Medicine News(10 mins):Health News:Electronic Security Specialists (E.S.S.C. Inc) Awarded Top Service Provider Award By Monitronics 2Health News:Journey Tickets at The Stadium of Fire at Lavell Edwards Stadium in Provo, Utah: Ticket Down Slashes Ticket Prices for Journey on the 4th of July in Provo 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 3Health News:Wound Care Advantage Hosts Its First UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Wound Care Advantage Hosts Its First UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Fireside Convalescent Hospital Proves Itself as a Leading Care Center in New Video 2
... breast cancer patient has to pay thousands of dollars as ... case against the doctor//. Doctor Robert Newton is the family ... case for negligent treatment as they feel that the doctor ... case against Dr. Newton for a compensation of $2million for ...
... seen when Pharma major Wockhardt limited (Thiruvananthapuram) in association with ... vaccine//, marketed the latest vaccine for Hepatitis A. ,Hepatitis ... to be taken to curb the spread of the disease. ... period of almost a month and spreads to humans through ...
... arguments can delay wound healing according to a new study ... New Scientist//. ,.,Researchers at Ohio State University College of ... about half hour daily can have delayed wound healing at ... also cause reduced body immunity. ,42 married couples whose ...
... stabilize the rates of HIV by the year 2020 has ... HIV infected individuals on a monthly basis//. It has also ... below 0.3 percent by 2010. The current projected population of ... recent government decision, poor HIV carriers living in communities are ...
... Her-2/neu positive was helped by her Wangaratta community to ... costs her more than $70,000.// The fund was raised ... could help her to buy Herceptin drug for one ... to chemotherapy and anti-estrogen therapy such as tamoxifen and ...
... novel finding that love and addiction may go hand ... physiological effects manifested as a result of dopamine release// ... than a simulation of the effects observed following drug ... and drug abuse leaves the user with an insatiable ...
Cached Medicine News:Health News:‘Marriage Squabbles’ bad for both Emotional and Physical Wound 2Health News:Love And Drug Addiction Share The Same Chemistry 2
... Dermalinfusion is the only treatment ... a topical dermaceutical while exfoliating ... all skin types and addresses ... conditions including hyperpigmentation, acne, photodamage, ...
... practices that require an increased energy rating ... versatility of the Clareon System enables you ... that would typically require multiple cosmetic lasers. ... obsolescence because the Clareon is specifically designed ...
Disposable. Sterile Suction Tubing....
Bi-phasic peristaltic infusion pump for tumescent work....
Medicine Products: